A selection of publications with educational value in
Interstitial Lung Disease
Most recently added articles listed first
- Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: A laboratory randomized trial in healthy humans
(Figure 1 of 10.1111/resp. 14580)
(Click image to enlarge)
Clara Bianquis, Camille Rolland-Debord, Isabelle Rivals, Thomas Similowski, Capucine Morélot-Panzini (DOI: 10.1111/resp.14580)
onlinelibrary.wiley.com/doi/10.1111/resp.14580/full (January 2024)Comment by Dr Mark Lavercombe:
The researchers in this fascinating study induced dyspnoea using thoracoabdominal loading in 32 healthy adults without respiratory disease and with normal body mass index. High-flow nasal cannulae were used to administer either FiO2 21% or 100%. Visual analogue ratings of dyspnoea were completed, and showed both high-flow therapies were associated with reduction in symptoms, with no difference between FiO2 21% or 100%. There were also reductions in patient reported chest tightness and work/effort sensations. The authors hypothesise that the mechanism was reduction in afferent-reafferent mismatch. Further studies in patients with respiratory disease are recommended.20231207 - Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
(Figure 1 of 10.1111/resp.14563)
(Click image to enlarge)
Joy Zhao, Joseph Fares, Gautam George, Arlene Maheu, Giorgos Loizidis, Jesse Roman, Daniel Kramer, Michael Li, Ross Summer (DOI: 10.1111/resp.14563)
onlinelibrary.wiley.com/doi/10.1111/resp.14563/full (November 2023)Comment by Dr Mark Lavercombe:
In this analysis of almost 50,000 patients with idiopathic pulmonary fibrosis from the TriNetX US Collaborative Network, the authors defined subgroups based on self-identified race and ethnicity. The results demonstrate a significantly lower rate of anti-fibrotic use in patients who identified as Black when compared with White (6.2% vs 11.4%, p <0.0001), Hispanic (10.8% vs. 20.2%, p <0.0001) and Asian (9.6% vs. 14.7%, p = 0.0006). Hispanic patients had higher usage of anti-fibrotics than Asian patients (21.1% vs. 16.3%, p = 0.012), and no other comparisons were significant. Sub-group analysis for patients over 65 or with lower FVC demonstrated a persistent difference between treatment in Black and White cohorts. These data suggest that patients identifying as Black in the United States are significantly less likely to be treated with anti-fibrotic therapies for IPF and further data is required to determine why.20231009 - Thoracic manifestations of IgG4-related disease Romain Muller, Mikael Ebbo, Paul Habert, Laurent Daniel, Antoine Briantais, Pascal Chanez, Jean Yves Gaubert, Nicolas Schleinitz (DOI: 10.1111/resp.14422)
(Figure 4 of 10.1111/resp. 14422)
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.14422/full (February 2023)Comment by Dr Mark Lavercombe:
This excellent review article collates the literature on IgG4-related disease and particularly its thoracic manifestations. The authors provide an overview of the pathogenesis which remains poorly understood, as well as the clinical and imaging features and a diagnostic algorithm. The identification of a paravertebral soft band on CT chest is relatively specific, while histology will vary depending on the type of tissue sampled. Corticosteroids and rituximab are shown to be effective therapies, although relapse can occur.20230109 - A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases Taiki Furukawa, Shintaro Oyama, Hideo Yokota, Yasuhiro Kondoh, Kensuke Kataoka, Takeshi Johkoh, Junya Fukuoka, Naozumi Hashimoto, Koji Sakamoto, Yoshimune Shiratori, Yoshinori Hasegawa (DOI: 10.1111/resp.14310)
(Figure 1 of 10.1111/resp.14310)
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.14310/full (September 2022)Comment by Dr Mark Lavercombe:
Using their cohort of 1068 consecutive patients with chronic interstitial lung diseases (ILD), the authors of this paper designed a two-step machine learning algorithm for the diagnosis of idiopathic pulmonary fibrosis (IPF) based on patient characteristics, imaging findings, blood tests and pulmonary function tests. Their algorithm can diagnose and differentiate IPF from other ILDs with similar accuracy to multi-disciplinary team (MDT) discussion. Further, patients with IPF diagnosed by artificial intelligence had a poorer prognosis even than those diagnosed with IPF at MDT. Validation on other cohorts is needed to confirm generalisability.20220809 
(Figure 2 of 10.1111/resp. 14234)
(Click image to enlarge)Direct and indirect cost of Systemic Sclerosis and associated Interstitial Lung Disease: A nationwide population-based cohort study Malene Knarborg, Anders Løkke, Ole Hilberg, Rikke Ibsen and Melina Gade Sikjær (DOI: 10.1111/resp.14223)
onlinelibrary.wiley.com/doi/10.1111/resp.14224/full (May 2022)Comment by Dr Mark Lavercombe:
This paper utilises extensive registry data and data linkage to evaluate the direct and indirect costs of a diagnosis of systemic sclerosis (SSc) with or without interstitial lung disease (SSc-ILD) compared with healthy controls in Denmark. The diagnosis of systemic sclerosis is associated with a significant increase in healthcare costs. Total excess costs are approximately 40% higher in those diagnosed with SSc-ILD than in those with SSc without ILD. In the years leading up to the diagnosis of SSc, there is no difference in socioeconomic status; however, a significant difference appears from two years prior and persists subsequently to diagnosis. These findings exemplify the financial burden a SSc diagnosis implies for healthcare systems and patients.20220406- Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis
Figure 1 of 10.1111/resp.14204
(Click image to enlarge)
Claudio Macaluso, Cristina Boccabella, Maria Kokosi, Nishanth Sivarasan, Vasilis Kouranos, Peter M George, George Margaritopoulos, Philip L Molyneaux, Felix Chua, Toby M Maher, Gisli R Jenkins, Andrew G Nicholson, Sujal R Desai, Anand Devaraj, Athol U Wells, Elisabetta A Renzoni, Carmel J W Stock
onlinelibrary.wiley.com/doi/10.1111/resp.14204/full (Mar 2022)Comment by Dr Mark Lavercombe:
Prediction of disease progression and prognosis in patients with interstitial lung disease remains a difficult problem. In this paper, the authors study a cohort of patients with fibrotic hypersensitivity pneumonitis from a single centre and attempt to demonstrate factors that predict mortality. Their finding that decline in lung function at one year predicts a reduced survival is important, but in this patient cohort even marginal declines in FVC and/or DLCO are highly predictive for mortality. This finding warrants further investigation at other centres.20220301 - Prevalence and prognostic impact of physical frailty in Interstitial Lung Disease: A prospective cohort study M A Malik Farooqi, Sachi O’Hoski, Sarah Goodwin, Nima Makhdami, Afia Aziz, Gerard Cox, Joshua Wald, Christopher J Ryerson, Marla K Beauchamp, Nathan Hambly and Martin Kolb (DOI: 10.1111/resp.14066)
Figure 1 of 10.1111/resp.14066
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.14066/full (Jul 2021)Comment by Dr Mark Lavercombe:
Frailty is an increasingly recognised prognostic marker in many conditions. Assessment for frailty using a simple five-point scale in this cohort of patients with fibrotic interstitial lung diseases demonstrates that frailty is common and associated with higher mortality, even after adjusting for ILD-GAP score. The authors suggest that frailty is potentially modifiable with pulmonary rehabilitation, although this will require further research.20210622 - Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data Marios Rossides; Susanna Kullberg; Daniela Di Giuseppe; Anders Eklund; Johan Grunewald; Johan Askling; Elizabeth V Arkema (DOI: 10.1111/resp.14001)
Figure 1 of 10.1111/resp.14001
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.14001/full (Jan 2021)Comment by Dr Mark Lavercombe:
In this paper, the authors apply a retrospective target trial emulation on a large dataset of patients with sarcoidosis from Sweden, to examine the difference in infection rates between those treated with methotrexate and azathioprine for their steroid-sparing effect. Their findings suggest an initial reduction in relative infection risk in those treated with methotrexate, although the difference reduced over time. Prospective data is needed to confirm this finding.20210422 - Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers Jessica Germaine Shull, Maria Teresa Pay, Carla Lara Compte, Miriam Olid, Guadalupe Bermudo, Karina Portillo, Jacobo Sellarés, Eva Balcells, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Diana Badenes-Bonet, Rosana Blavia, Pilar Rivera-Ortega, Amalia Moreno, Jordi Sans, Damià Perich, Silvia Barril, Leonardo Esteban, Laia Garcia-Bellmunt, Jordi Esplugas, Guillermo Suarez-Cuartin, Jaume Bordas-Martinez, Diego Castillo, Rosa Jolis, Inma Salvador, Saioa Eizaguirre Anton, Ana Villar, Alejandro Robles-Perez, M Josefa Cardona, Enric Barbeta, Maria Guadalupe Silveira, Claudia Guevara, Jordi Dorca, Antoni Rosell, Patricio Luburich, Roger Llatjós, Oriol Jorba And Maria Molina-Molina (DOI: 10.1111/resp.13973)
Figure 2 of 10.1111/resp.13973
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13973/full (Apr 2021)Comment by Dr Mark Lavercombe:
In this fascinating study, the authors combine both modelled and measured air quality data from the Catalonia region of Spain with data from the Observatory IPF.cat registry. A potential link between higher exposure to PM2.5 pollutants and the development of idiopathic pulmonary fibrosis is suggested, although further research is clearly required to delineate causation.20210323 - Risk of cancer incidence in patients with idiopathic pulmonary fibrosis: A nationwide cohort study Hong Yeul Lee, MD; Jinwoo Lee, MD; Chang-Hoon Lee, MD; Kyungdo Han, PhD; Sun Mi Choi, MD (DOI: 10.1111/resp.13911)
Figure 2 of 10.1111/resp. 13911
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13911/full (Feb 2021)Comment by Dr Mark Lavercombe:
In this large study of over 100,000 patients in the Korea NHIS, the association between a diagnosis of IPF and malignancy is explored. Overall cancer risk is confirmed to be higher (HR-2), largely driven by a significant excess in lung cancer diagnoses (HR-6).20210120 - Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinic Anna E B Mclean, Susanne E Webster, Margaret Fry, Edmund M Lau, Peter Corte, Paul J Torzillo, Lauren K Troy, Helen E Jo, Monika Geis, Jessica E Rhodes, Shannon Cleary, Lissa Spencer and Tamera J Corte
Figure 1
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13913/full (January 2021)Comment by Dr Mark Lavercombe:
This authors describe the functions of a multidisciplinary ILD clinic at a tertiary referral centre, expanding on the accepted role in multidisciplinary diagnosis to provide ongoing access to specialist physicians, nurses and physiotherapists in one setting. The patient perspective is provided by the use of instructive quotes from patient survey responses.20201222 - Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study Mark G Jones, Christopher R Hillyar, Anjan Nibber, Alison Chisholm, Andrew Wilson, Toby M Maher, Alan Kaplan, David Price, Simon Walsh, Luca Richeldi, On Behalf of the Respiratory Effectiveness Group's Interstitial Lung Disease Working Group
Figure 3
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13836/full (December 2020)Comment by Dr Mark Lavercombe:
This study demonstrates that patients with an eventual diagnosis of interstitial lung disease will utilise more healthcare resources in the years leading to their ILD diagnosis, perhaps suggesting that earlier diagnosis is possible. Recognition of potential ILD can have an important impact on appropriate referral, diagnosis and management options, especially when considering agents that affect disease progression in IPF, or specific treatments for ILD associated with other conditions like CTD.20201118 - Artificial stone-associated silicosis in China: A prospective comparison with natural stone-associated silicosis Na Wu. Changjiang Xue. Shiwen Yu. Qiao Ye
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13744 (May 2019)Comment by Dr Mark Lavercombe:
In a cohort of 81 patients presenting with silicosis to a single centre in China, artificial stone exposure is associated with shorter latency to disease onset, and more rapid radiologic progression and reduction in lung function, when compared with those exposed to natural stone. This paper further contributes to the data surrounding accelerated silicosis in workers exposed to artificial stone that has been noted in multiple countries in recent years.20190520 - Bidirectional association between tuberculosis and sarcoidosis Sheng-Huei Wang, Chi-Hsiang Chung, Tsai-Wang Huang, Wen-Chiuan Tsai, Chung-Kan Peng, Kun-Lun Huang, Wann-Cherng Perng, Chih-Feng Chian, Wu-Chien Chien and Chih-Hao Shen
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13482 (May 2019)Comment by Dr Mark Lavercombe:
This cohort study demonstrates the difficulty of differentiating sarcoidosis and tuberculosis. The diagnosis of tuberculosis within one year of sarcoidosis diagnosis occurred at a significant rate, suggesting the possibility of misdiagnosis. Further, subsequent diagnosis of sarcoidosis in patients treated for tuberculosis is significant after the first year of follow-up.20190423 - Pulmonary infarction secondary to pulmonary embolism: An evolving paradigm Marjan Islam, Jason Filopei, Matthew Frank, Navitha Ramesh, Stacey Verzosa, Madeline Ehrlich, Eric Bondarsky, Albert Miller and David Steiger
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13299 (Sep 2018)Comment by Dr Mark Lavercombe:
This paper describes the findings of a retrospective review of 367 patients from a single centre who presented with pulmonary embolism. Pulmonary infarction was associated with younger age, absence of cardiopulmonary disease, presence of pleuritic chest pain and presence of an ipsilateral pleural effusion. Explanations based on pulmonary blood flow physiology and the development of collateral supply are proposed.20180823 - S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension Argyrios Tzouvelekis, Jose D Herazo-Maya, Changwan Ryu, Jen-Hwa Chu, Yingze Zhang, Kevin F Gibson, Percy K Adonteng-Boateng, Qin Li,1 Hongyi Pan, Benjamin Cherry, Ferhaan Ahmad, Hubert J Ford, Erica L Herzog, Naftali Kaminski and Wassim H Fares
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13302 (Jul 2018)Comment by Dr Mark Lavercombe:
This intriguing study suggests the use of serum SA100A12 concentration as a prognostic marker in pulmonary hypertension. Despite relatively small sample sizes, elevated S100A12 levels were significantly associated with a diagnosis of PH, and negatively correlated to cardiac output. Increased overall mortality was associated with S100A12 levels in both discovery and validation cohorts.20180717 - Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization Gregory J Keir, S John Wort, Maria Kokosi, Peter M George, Simon L F Walsh, Joseph Jacob, Laura Price, Simon Bax, Elisabetta A Renzoni, Toby M Maher, Peter Macdonald, David M Hansell and Athol U Wells
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13250 (Jun 2018)Comment by Dr Mark Lavercombe:
The use of transthoracic echocardiography as a screening tool for pulmonary hypertension in patients with interstitial lung disease is explored in this study, which finds significant numbers of patients are misclassified based on TTE parameters. The possibility of a combined risk assessment using other clinical factors is suggested.20180620 - Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema Joseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, Ronald Karwoski, Arjun Nair, Simon L F Walsh, Joseph Barnett, Gary Cross, Eoin P Judge, Maria Kokosi, Elisabetta Renzoni, Toby M Maher and Athol U Wells (DOI: 10.1111/resp.13231)
(Click image to enlarge)
onlinelibrary.wiley.com/... (Jun 2018)Comment by Dr Mark Lavercombe:
In this study, the authors seek to define the risks of pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema compared with those with IPF alone. Their conclusion that CPFE is "not greater than the sum of its parts" helps guide prognostication in this patient cohort.20180523 - Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections Lonny Yarmus, Phan T Nguyen, Kristina Montemayor, Mark Jennings, Brett Bade, Majid Shafiq, Gerard Silvestri, Daniel Steinfort
onlinelibrary.wiley.com/doi/10.1111/resp.13306 (Apr 2018)20180430 - Diagnostic utility of surgical lung biopsies in elderly patients with indeterminate interstitial lung disease Laszlo T Vaszar, Brandon T Larsen, Karen L Swanson, Jay H Ryu, Henry D Tazelaar (DOI: 10.1111/resp.13223)
(Click image to enlarge)
onlinelibrary.wiley.com/doi/full/10.1111/resp.13223 (Apr 2018)Comment by Dr Mark Lavercombe:
Surgical lung biopsy for pathological correlation with the clinico-radiologic diagnosis in idiopathic interstitial pneumonia is associated with a risk of morbidity and mortality. These risks increase with age. In this retrospective cohort of elderly patients (≥75y), the authors demonstrate that biopsy features were not those of UIP in 39% of cases where HRCT was inconsistent with UIP. This diagnostic benefit is countered by significant 30- and 90-day mortality.20180420 - Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD Jean P Du Plessis, Senan Fernandes, Rakin Jamal, Pat Camp, Kerri Johannson, Michele Schaeffer, Pearce G Wilcox, Jordan A Guenette and Christopher J Ryerson (DOI: 10.1111/resp.13226)
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13226/full (Apr 2018)Comment by Dr Mark Lavercombe:
Clinicians have long relied on extrapolation of data from COPD studies to inform decision making around oxygen supplementation in patients with other chronic lung diseases. This study demonstrates a difference between patients with fibrotic ILDs and COPD in the degree of exertional oxygen desaturation, raising important questions about the appropriateness of extrapolation.20180320 - Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep Amanda J Piper, Stephen J Wort, Elisabetta A Renzoni, Vasileios Kouranos (DOI: 10.1111/resp.13273)
onlinelibrary.wiley.com/doi/10.1111/resp.13273/full (Feb 2018)20180313 - Serial chest CT in cryptogenic organizing pneumonia: Evolutional changes and prognostic determinants Man P Chung, Bo D Nam, Kyung S Lee, Joungho Han, Jai S Park, Jung H Hwang, Min J Cha and Tae J Kim (DOI: 10.1111/resp.13188)
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.13188/full (Mar 2018)Comment by Dr Mark Lavercombe:
This paper describes the radiological follow-up of patients treated for cryptogenic organising pneumonia and demonstrates a high proportion of patients have residual radiologic abnormality. Several factors associated with persisting abnormalities are identified, including extent of consolidation and treatment duration.20180215 Two position statements on interstitial lung disease
- Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia: Helen E Jo, Lauren K Troy, Gregory Keir, Daniel C Chambers, Anne Holland, Nicole Goh, Margaret Wilsher, Sally de Boer, Yuben Moodley, Christopher Grainge, Helen Whitford, Sally Chapman, Paul N Reynolds, Ian Glaspole, David Beatson, Leonie Jones, Peter Hopkins, Tamera J Corte
(Click image to enlarge)
10.1111/resp.13146 (Oct 2017)20171014 - The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia: Jyotika D Prasad, Annabelle Mahar, Jane Bleasel, Samantha J Ellis, Daniel C Chambers, Fiona Lake, Peter M A Hopkins Tamera J Corte, Heather Allan, Ian N Glaspole
Figure 1
(Click image to enlarge)
10.1111/resp.13163 (Oct 2017)20171014
- Managing patients with interstitial lung disease: Two more pieces of the puzzle: Francesco Macagno, Paolo Maria Leone, Luca Richeldi
10.1111/resp.13195 (Nov 2017)20171014
- CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis: Mitsuaki Yagi, Hiroyuki Taniguchi, Yasuhiro Kondoh, Masahiko Ando, Tomoki Kimura, Kensuke Kataoka, Taiki Furukawa, Atsushi Suzuki, Takeshi Johkoh & Oshinori Hasegawa.
(Click image to enlarge)
10.1111/resp.13066 (Oct 2017)Comment by Dr Mark Lavercombe:
The PA:A ratio as measured on chest CT scan has been demonstrated to predict pulmonary hypertension in some studies. In this cohort PA:A > 0.9 is found to predict both elevated mPAP and survival in patients with idiopathic pulmonary fibrosis.20170920 - Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease, Kathryn M Milne, Joanne M Kwan, Sabina Guler, Tiffany A Winstone, Angela Le, Nasreen Khalil, Pat G Camp, Pearce G Wilcox & Christopher J Ryerson
(Click image to enlarge)
10.1111/resp.12944 (May 2017)Prognosis in patients with fibrotic interstitial lung diseases can vary significantly. In this study, the authors demonstrate that Frailty is highly prevalent in a cohort of patients with fibrotic ILD and strongly associated with dyspnoea severity. The authors propose a potential role for frailty assessment in identifying patients at risk of complications from invasive procedures or medical therapies, and/or mortality.
20170415 Pulmonary Rehabilitation Guidelines for Australia and New Zealand Jennifer A Alison, Zoe J McKeough, Kylie Johnston, Renae J McNamara, Lissa M Spencer, Sue C Jenkins, Catherine J Hill, Vanessa M McDonald, Peter Frith, Paul Cafarella, Michelle Brooke, Helen L Cameron-Tucker, Sarah Candy, Nola Cecins, Andrew S L Chan, Marita T Dale, Leona M Dowman, Catherine Granger, Simon Halloran, Peter Jung, Annemarie L Lee, Regina Leung, Tamara Matulick, Christian Osadnik, Mary Roberts, James Walsh, Sally Wootton, Anne E Holland, on behalf of the Lung Foundation Australia and the Thoracic Society of Australia and New Zealand 10.1111/resp.13025 (Apr 2017)
The aim of these Guidelines is to provide evidence-based recommendations for the practice of pulmonary rehabilitation (PR) specific to Australian and New Zealand healthcare contexts.
These first-ever pulmonary rehabilitation Guidelines for Australia and New Zealand were launched (24-28 March 2017) at the TSANZSRS Annual Scientific Meeting in Canberra, Australia (24-28 March 2017), and were drawn up following a systematic review of over 275 clinical trials.
The Guidelines recommend that all COPD patients should be offered pulmonary rehabilitation regardless of their disease severity.
See the full Editorial for these important Guidelines at onlinelibrary.wiley.com/doi/10.1111/resp.13039/full
20170329- Bronchoscopy assessment of acute respiratory failure in interstitial lung disease Antonella Arcadu & Teng Moua DOI: 10.1111/resp.12909
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.12909/full (Feb 2017)Comment by Dr Mark Lavercombe:
This study examines the utility of bronchoscopy in patients admitted with acute exacerbations of interstitial lung disease. Although a relatively low diagnostic yield is identified, significant potential complications are noted and there is no in-hospital mortality benefit seen in those undergoing the procedure.20170131 - Clinical impact of the interstitial lung disease Multidisciplinary service, Jo et al. DOI: 10.1111/resp.12850
(Click image to enlarge)
onlinelibrary.wiley.com/doi/10.1111/resp.12850/full (Jul 2016)Comment by Dr Mark Lavercombe:
This study demonstrates that assessment of the diagnosis and management of interstitial lung diseases by an expert multidisciplinary panel can potentially make a major contribution to patient outcomes. A significant proportion of patients is re-classified after MDT discussion, leading to changes in management. Longer term follow-up of patient outcomes might add weight to the use of MDT discussions.20161021 Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Hanada et al.
onlinelibrary.wiley.com/doi/10.1111/resp.12807/abstract (May 2016)
(FREE access: Editor's Choice; Editorial: onlinelibrary.wiley.com/doi/10.1111/resp.12843/abstract)20160819Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study. Hamada et al.
onlinelibrary.wiley.com/doi/10.1111/resp.12665/abstract (Nov 2015)20160819
